Preliminary Results of the “Sovet” Observational Program for Use of Natalizumab in the Treatment of Patients with Remitting Multiple Sclerosis
Crossref DOI link: https://doi.org/10.1007/s11055-014-9943-0
Published Online: 2014-05-14
Published Print: 2014-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Popova, E. V.
,
Brylev, L. V.
Davydovskaya, M. V.
Text and Data Mining valid from 2014-05-14